Advertisement

Topics

Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics

13:29 EDT 6 Jun 2018 | Pharmaceutical Processing

The companies have entered into a license agreement regarding a collaborative licensing, research, and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).
Contributed Author: 
Hsiri Therapeutics, Inc.
Topics: 

Original Article: Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics

NEXT ARTICLE

More From BioPortfolio on "Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics"

Advertisement
Quick Search
Advertisement
Advertisement